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Background: Recent studies in patients with rheumatologic conditions support the importance of inflammation in the development of atherosclerosis. Moreover, targeting inflammation upstream with biological agents for atherosclerosis progression has become the focus of intense research. Whilst biologics suppress inflammation, they increase serious infection (SI) risk. We hypothesised that biologic therapy interruption due to SI in patients would lead to rebound inflammation and more major adverse cardiovascular events (MACE) compared to those with no interruption.
Methods: We retrospectively analysed a cohort of 265 patients above the age 18 who received biologics for rheumatoid arthritis; ankylosing spondylitis; and psoriatic arthritis with regular follow-ups. Patient characteristics, biologic therapy interruptions, SIs and MACE (non-fatal MI, non-fatal stroke and cardiovascular death) were captured in detail. Patients were categorised into 3 groups for analysis: (1) pause AND SI, (2) pause AND no SI, and (3) no pause.
Results:
Baseline characteristics were similar between the groups. A total of 357 pauses in biologic therapy was noted among 152 patients, of which 39 (11%) were observed in 25 patients due to SI. A significantly higher rate of MACE was observed in the group who paused for SI compared to others (Figure) . Also, whilst pausing biologic therapy due to SI was associated with an increased incremental odds of experiencing MACE [OR 4.08 (95% CI 1.21-13.74), p = 0.023], pausing biologics for other reasons was not [OR 1.17 (95% CI 0.41-3.29), p = 0.77].Conclusions: In rheumatic patients, biologic therapy interruption due to SI leads to increased MACEs. Method: Using the Coronary Angiogram Database of South Australia (CADOSA), 205 AF patients undergoing PCI in 2015-16 were identified. One-year outcomes were compared between patients prescribed (1) Dual Therapy (OAC+1 antiplatelet), or (2) DAPT at discharge against Triple Therapy (OAC+DAPT). The primary endpoint was bleeding (as per International Society on Thrombosis and Haemostasis) and the secondary endpoint was TEE (MI, stroke and systemicembolism).
Results: At discharge, 60% of patients were prescribed DAPT (72 ± 11 yrs, 30% female), 32% Triple Therapy (76 ± 10 yrs, 29% female) and 8% Dual Therapy (76 ± 18 yrs, 24% female).
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Conclusion:
In this real-world setting of AF patients receiving PCI, the risk of bleeding was lower in patients discharged on dual therapy and DAPT, with a trend for lower TEE, compared to triple therapy. This small study suggests acceptability of a clinical benefit of dual therapy in this scenario so that further investigation in larger studies is warranted. 
